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ABSTRACT 
 
For simultaneous validating anassay of Aspirin, Clopidogrel and Rosuvastatin in Capsule Dosage Form, a simple, 
precise and accurate RP-HPLC method has been developed. Isocratic RP-HPLC process was established on BDS 
hypersil C18 (250mm×4.6mm internal diameter, 5µ particle size) using mobile phase as 0.05M Potassium 
DihydrogenOrtho Phosphate (pH-4.0): Acetonitrile (60:40v/v) at a flow rate of 1.0 mL/min and at 235 nm the 
detection was carried out by using tunable absorbance detector (Waters 486). Forced degradation study was 
performed by acid, base and thermal degradation, as well as oxidation of the drug. The process was validated for 
accuracy, precision, linearity, and robustness. The method was found to be linear in the 15-45 𝜇g/mL of 
concentration range with 0.9988, 15-45 𝜇g/mL with 0.9983 and 2-6 𝜇g/mL with 0.9993 of correlation coefficient for 
Aspirin, Clopidogrel and Rosuastatin, respectively. Degradation products formedbecause of stress studies, did not  
interfere with the Aspirin, Clopidogrel and Rosuvastatin detection; consequently, the assay can be advised to be 
stability indicating. 
 
Keywords: HPLC, Aspirin, Clopidogrel and Rosuvastatin, Validation, Forced degradation. 
Introduction 
Aspirin’sempirical formula is C9H8O4and its IUPAC 
name is 2-acetyloxybenzoic acid[1].Figure 1 shows 
chemical structure of Aspirin. Chemically Aspirin is a 
non-selective cyclo-oxygenase inhibitor and used as an 
antipyretic, analgesic, anti-inflammatory and 
antithrombotic agent [2-6]. It reduces non-fatal 
myocardial infarction. Clopidogrel’s empirical formula 
is C16H16ClNO2S and its IUPAC name is methyl (2S)-
2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-
c]pyridin-5-yl)acetate[7,8]. Figure 2 shows the 
chemical structure of Clopidogrel. It is used an 
antiplatelet agent, Platelet Aggregation Inhibitor, 
Fibrinolytic Agents.It is a P2Y12 adenosine 
diphosphate receptor irreversible inhibitor present on 
the platelet cells membrane [8-10].  
___________________________ 
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Rosuvastatin’sempirical formula is C22H28FN3O6S as 
well as its IUPAC name is (E,3R, 5S)-7-[4-(4-
fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-
propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic 
acid.Chemical structure of Rosuvastatin has shown in 
figure 3.It is an antilipemic agent that competitively 
inhibits 3- hydroxry- 3-methyl glutaryl coenzyme A 
(HMGCoA) reductase. HMG-CoA reducutase 
catalyzes the HMG-CoA to mevalonic acid conversion, 
a Cholesterol precursor, the rate-limiting step in 
biosynthesisof cholesterol. The Drug is belonging to a 
class of medicines which is therapeutically used to 
decrease a levels of plasma cholesterol and protect 
from cardiovascular disease as well asreported for the 
use in the dyslipidemia and hypercholesterolemia 
treatment[11-14]. 
These chemical agents are official reported in Indian, 
British and United States Pharmacopoeia.Previous 
reportsdisclose that quantitative analysis ofAspirin, 
Clopidogrel and Rosuvastatin have been done 
separately on in combination of two and in 
combination of other drugs but no method is reported 
for the simultaneous estimation of Aspirin, Clopidogrel 
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and Rosuvastatin in combined dosage form through 
HPLC.The present study involved the development and 
validation of RP-HPLC method for estimateAspirin, 
Clopidogrel and Rosuvastatin in combined 
pharmaceutical dosage form and their stability study. 
 
Material and methods 
Instruments 
The liquid chromatographic system contains Waters 
series M510 equipped with a tunable absorbance 
detector (Waters 486), HPLCpump (Waters 510), 
andmanual injectorrheodynevalve with 20 𝜇L fixed 
loop.The analysiswasobserved at 235 nm wavelength. 
Chromatographic analysis was runon Thermo 
scientificBDS hypersil C18, (250mm × 4.6mm internal 
diameter, 5µ particle size).Citizen electronic balance 
were used for weigh measurement of chemicals and 
drugs.Chemiline India pH meter and 
ToshconUltrasonicator was used. 
 
Chemicals and reagents 
Acetonitrile and Methanol were of HPLC grade 
obtained from Merk Ltd., Mumbai. Water was of 
HPLC grade prepared by triple distillation method. 
Potassium DihydrogenOrtho Phosphate, Ortho 
Phosphoric Acid (OPA), Sodium Hydroxide (NaOH), 
Hydrogen Peroxide (H2O2) and Hydrochloric Acid 
(HCl)were of AR grade and were obtained from 
Merck, Mumbai India.Aspirin (ASP), Clopidogrel 
(CLP) and Rosuvastatin (ROS) reference standards 
obtained as gift samples from FDC limited, 
Mumbai.Capsules as brand name of Rosumac Gold 
containing 10 mg of Rosuvastatin 75mg ofClopidogrel 
and 75 mg of Aspirin manufactured by 
MacleodsPharmaceuticales Ltd. was procured from 
local market. 
 
HPLC Condition 
The mobile phase consisted of 0.05M Potassium 
Dihydrogenortho Phosphate (pH-4.0): Acetonitrile 
(60:40v/v).The freshly mobile phase was made and 
ToshconUltrasonicatorsonicatedwas used for 
sonication for 5 min before use. BDS hypersil C18, 
(250mm×4.6mm internal diameter, 5µ particle size) 
was used and for the period of half an hour it was 
equilibrated with themobile phase flowing through the 
system.TheHPLC and column were placed at 
atmospherictemperature.At 235 nm of wavelength, 
eluent was observed by UV detection. Analysis was 
done at flowrate of 1.0ml/min with 20μl volume of 
injection. All data were analyzed by using Empower 3 
software. 
 
Preparation of Mobile Phase 
The mobile phase was prepared by mixing 0.05M 
Potassium DihydrogenOrtho Phosphate (pH-4.0) and 
Acetonitrile in the ratio of (60:40%v/v). The solution 
was then filtered through 0.45 microns membrane filter 
and degassed. 
 
Preparation of 0.05M Potassium Dihydrogen Ortho 
Phosphate (pH-4.0) 
Take about 6.80gm Potasiumdihydrogenortho 
phosphate into a 1000ml beaker. Add 800ml water and 
dissolve. Adjust ph 4.0 of this solution with 1% 
Orthophosphoric acid. Make up volume up to 1000ml 
with water. 
 
Preparation of standard solution 
Standard stock solution of Aspirin, Clopidogrel and 
Rosuvastatinwere prepared by accurately weighing 
30mg, 30mg and 40mg respectively and dissolving 
them separately in 100ml with methanol to 
preparesolution of 300𝜇g/mL, 300𝜇g/mL and 
400𝜇g/mL. The solution of Rosuvastatin was further 
diluted by taking 10 ml of standard stock solution and 
diluted upto 100 ml with methanol separately to 
prepare solution of40𝜇g/mL. 
 
Forced Degradation Study 
Preparation of solution for acid degradation  
The study of acid decomposition was made by keeping 
the working solution of all three drugs (1 ml) in 2 ml of 
0.1N HCl for 4.5 hrs. After 4.5hrs solution neutralized 
with 2ml 0.1N NaOH and finallyprepared up to 10 ml 
volume with mobile phase, sonicated and filtered 
byfilter paper of 0.45μm membrane then injected in to 
HPLC system. Degradation samples were prepared as 
blank sample, separate standard samples and combined 
sample of all three drugs. 
 
Preparation of solution for basic degradation  
The study of alkali decomposition was done by 
keeping the working solution of all three drugs (1 ml) 
in 2 ml of 0.1N NaOH for 5 hrs. 5 hrslater solution 
neutralized with 2 ml of 0.1N HCL and lastlyprepared 
up to 10 ml volume with mobile phase, sonicated and 
filtered by filter paper of 0.45μm membrane then 
injected in to HPLC system. Degradation samples were 
prepared as blank sample, separate standard samples 
and combined sample of all three drugs. 
 
Preparation of solution for oxidative degradation   
The study of oxidative decomposition was achieved by 
keeping the working solution of all three drugs (1 ml) 
in 2 ml 3% H2O2 for 4 hrs. 4hrslater volumeprepared 
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up to 10 ml with mobile phase, sonicatedthen filteredby 
filter paper of 0.45μm membrane then injected in to 
HPLC system. Degradation samples were prepared as 
blank sample, separate standard samples and combined 
sample of all three drugs. 
 
Preparation of solution for thermal degradation  
The study of thermal decomposition was achieved by 
refluxing the working solution of all three drugs (1 ml) 
for 3 hrs at 105 ºC. 4.5hrslater volumeprepared up to 
10 ml volume with mobile phase, sonicatedthen 
filteredby filter paper of 0.45μm membrane then 
injected in to HPLC system. Degradation samples were 
prepared as blank sample, separate standard samples 
and combined sample of all three drugs. 
 
Preparation of solution for UV degradation  
UV degradation was done by exposing the working 
solution of both drugs (1ml) to Sunlight for 210 
minutes. 3.5 hours later volume prepared up to 10 ml 
volume with mobile phase, sonicatedthen filteredby 
filter paper of 0.45μm membrane then injected in to 
HPLC system. Degradation samples were prepared as 
blank sample, separate standard samples and combined 
sample of all three drugs. 
 
Determination of λ max 
The UV spectra of standard stock solutions of Aspirin, 
Clopidogrel and Rosuvastatintaken between the wave 
length ranges of 200-400nm using methanol as 
blank.the λ max was found to be 216.11 nm, 215.39 nm 
and 243.97 nm for Aspirin, Clopidogrel and 
Rosuvastatinrespectively. Overlay of the three spectra 
taken and iso-absorptive point was selected and it was 
found that all three drugs show appreciable absorbance 
at 235 nm, so it is used for the further study (Figure 4).  
 
Procedure of Analysis 
1ml from Aspirin Standard stock solution, 1ml from 
ClopidogrelStandard stock solution and 1ml from 
RosuvastatinStandard stock solution were taken and 
volume was make up to 10ml with Mobile phase to 
obtain Working standard solution containing Aspirin 
(30𝜇g/mL), Clopidogrel (30𝜇g/mL) and 
Rosuvastatin(4𝜇g/mL). 
For Sample stock solution capsule powder was 
weighed equivalent to 30mg of Aspirin, 30mg of 
Clopidogrel and 4mg of Rosuvastatin into a 100ml 
volumetric flask. Add 60ml methanol and shake for 15 
minutes. Make up volume with methanol upto 100ml. 
Filter this solution with whatman filter paper no-1. to 
prepare sample stock solution of Clopidogrel 
(300𝜇g/ml), Aspirin (300𝜇g/ml) and Rosuvastatin 
(40𝜇g/ml). 1ml from Sample stock solution was taken 
into a 10ml volumetric flask and make up with mobile 
phase to obtain Working sample solution of 
concentration Clopidogrel (30𝜇g/mL), Aspirin 
(30𝜇g/mL) and Rosuvastatin (4𝜇g/mL) respectively. 
 
The contents of standard and sample solution were then 
filtered through 0.45 µm syringe filter. Chromatograms 
standard solution (six replicates) was recorded. A 
typical chromatogram ofAspirin, Clopidogreland 
Rosuvastatinare presented in figure 5. The 
retentiontime ofAspirin, Clopidogrel and 
Rosuvastatinwere 6.89 min, 5.51 min and 10.00 min 
respectively. The areas of peaks were measured and the 
quantitation was performed by inserting these values to 
the regression equation of calibration curve(Table 1). 
Optimized Chromatographic Condition: 
Stationary phase:Thermo scientific BDS hypersil C18 
(250mm × 4.6mm, 5µ). 
Mobile phase:Potassium dihydrogenortho phosphate 
(pH 4.0) : Acetonitrile (60:40) 
Flow rate :1.0ml/min 
Run time (min) :14min 
Detection:At 235 nm 
Injection (volume) :20μl 
 
 
Method validation procedure 
The developed method was validated for the 
parameters listed in ICH guidelines. 
Linearity 
The method was linear in the range of 15-45 𝜇g/mL, 
15-45𝜇g/mL and 2-6 𝜇g/mL for Aspirin, Clopidogrel 
and Rosuvastatin respectively. The linear correlation 
coefficient for Aspirin, Clopidogrel and 
Rosuvastatinwere found to be 0.9988, 0.9983 and 
0.9993 respectively, and are recorded in table 2, 3 and 
4. Calibration curve of Aspirin, Clopidogrel and 
Rosuvastatin was obtained by plotting the peak area 
ratio versus the respective concentrations (Figure 6, 7 
and 8).  
 
Accuracy  
The accuracy of the method was resolved by recovery 
experiments. Identified amount of working standard 
was added to the fixed concentration of the pre-
analyzed Capsule.By measuring the area before and 
after the addition of working standard,percent recovery 
was determined.Recovery was performed in the same 
wayfor altogetherthree drugs. The recovery studies 
were carried out in triplicate and outcomes are noted in 
table 5.This standard addition method was carried out 
at 80%, 100%, 120% level and the percentage recovery 
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was determined. Percent recovery was within the range 
of 98.733% to 99.409% for Aspirin (ASP), 98.803% to 
99.165% for Clopidogrel (CLP) and 100.546% to 
100.945% for Rosuvastatin (ROS)which shows that the 
method was accurate. 
 
Precision  
For the precision study, repeatability study was carried 
out for short time interval under the same 
chromatographic condition. The sample was injected in 
six replicate. The peak area for all the six replicate was 
recorded. The mean and % relative standard deviation 
(%RSD) was calculated and the results are shown in 
table 6. The %RSD for Aspirin (ASP), Clopidogrel 
(CLP), Rosuvastatin (ROS) were found to be 0.50%, 
0.76% and 1.14% respectively. From the data found the 
developed RP-HPLC method was found to be precise. 
For inter-day and intra-day precision three different 
concentrations (50%, 100% and 150% of analyte) of 
standard solutions were injected on same day and three 
consecutive days in three replicates and results were 
recorded in table 7 & 8. 
 
Limit of Detection (LOD) and Limit of 
Quantification (LOQ) 
The limit of detection and quantification were 
determinedby standard deviation of response and slope 
of the calibration curve and results are recorded table 9. 
The LOD for Aspirin (ASP), Clopidogrel (CLP), 
Rosuvastatin (ROS) was found to be 2.210μg/ml, 
2.614μg/ml and 0.219μg/ml respectively. The LOQ is 
the lowest concentration of the analyte, which 
providesresponse that can be exactly quantified. The 
LOQ for Aspirin (ASP), Clopidogrel (CLP), 
Rosuvastatin (ROS) was 6.696μg/ml, 7.922μg/ml and 
0.664μg/ml. 
 
Robustness 
Robustness of the method was analyzed by making 
minor changes in conditions like mobile phase ratio, 
pH of buffer, and flowrate in chromatograph and the 
outcome were documented in table 10. As per 
observation there were no noticeable changes in 
chromatograms and % relative standard deviation was 
found below 2%, which confirmed that the developed 
RP-HPLC method is robust. 
 
Specificity 
The specificity of proposed method is justified by the 
chromatograms of blank, placebo, standard and sample 
solutions under same chromatographic conditions 
shown in figure 9. The placebos did not interfere in 
determination of Aspirin (ASP), Clopidogrel (CLP), 
Rosuvastatin (ROS) in commercial Capsule.Specificity 
of the developed method was also assessed by applying 
different stress conditions (oxidation, acid, base, 
thermal and photolytic) to Aspirin (ASP), Clopidogrel 
(CLP), Rosuvastatin (ROS) Capsule. 
 
Degradation Study 
From the results of forced degradation studies showed 
that these components does not remained intact under 
stressed conditions and hence special storage 
conditions should be provided for the dosage form. The 
specificity studies showed that the principle peaks were 
well resolved (peak purity 99.99%) and free from any 
interference from the degradation product. The stress 
conditions were applied and degraded products of all 
three drugs are compared and showed in table 10 and 
chromatograms are in figure 10. From the stress studies 
it is concluded that substantial degradation of ASP, 
CLP and ROS occurred in acid, basic, oxidative 
thermal and photolytic stress conditions. The 
degradation products (impurities) in addition to percent 
degradation under acid, base, oxidation, thermal and 
photolytic stresses have unique retention times (RT) to 
acidic stress (8 impurities, RT: 2.21 min, 2.58 min, 
3.92 min, 5.00 min, 6.15 min, 7.82 min, 8.76 min, and 
11.30 min), basic stress (7 impurities, RT: 2.38 min, 
2.78 min, 5.03 min, 6.07 min, 7.84 min, 8.76 min and 
11.39 min), oxidative stress (8 impurities, RT: 2.32 
min, 2.71 min, 3.91 min, 5.05 min, 6.12 min, 7.80 min, 
8.74 min and 11.42 min), thermal stress (10 impurities, 
RT: 2.66 min, 2.88 min, 3.107 min, 4.17 min, 4.99 
min, 6.08 min, 6.61 min, 7.91 min, 8.86 and 11.29 min) 
and photolytic stress (10 impurities, RT: 2.66 min, 2.83 
min, 3.12 min, 4.01 min, 4.98 min, 6.07 min, 6.35 min, 
7.92 min, 8.88 min and 11.27 min). Degradation 
studies justified the method specificity for its intended 
application. 
 
RESULTS AND DISCUSSION 
Numerous compositions of mobile phase were tried for 
developing a novel RP-HPLC method.A suitable 
separation and good peak symmetry was found with 
Thermo scientific BDS hypersil C18, 250mm×4.6mm 
internal diameter, 5µ particle size or equivalent column 
and mobile phase comprising ofAcetonitrile: Buffer 
(0.05M potassium dihydrogenortho-phosphate) pH 4.0 
with orthophosphoric acid (40:60v/v) at a flow rate of 
1.0 ml/min to get improved reproducibility and 
repeatability. Quantification was performed with UV 
detection at 235 nm wavelength based on peak area. 
The retention time forAspirin, Clopidogrel and 
Rosuvastatin were determined as5.54 min, 6.93 min 
and 10.04 min, respectively. 
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According to ICH guidelines the optimized method 
was validated. The system appropriateness parameters 
were detected by this optimized condition. The method 
was found to be linear in the concentration range of 
15–45𝜇g/mL with correlation coefficient of 0.9988 for 
Aspirin, 15–45𝜇g/mL with correlation coefficient of 
0.9983 for Clopidogrel and 2–6𝜇g/mL with correlation 
coefficient of 0.9993 forRosuastatin. The outcomes of 
recovery study (98.733% to 99.409% for ASP, 
98.803% to 99.165% for CLP and 100.546% to 
100.945% for ROS) propose that the method has 
decent recovery. The precision of the projected method 
was carried in terms of the repeatability. The low% 
RSD (<2) values of 0.50%, 0.76% and 1.14% variation 
for Aspirin, Clopidogrel and Rosuastatin respectively, 
exposes that the projected method is precise. The LOD 
and LOQ values for Aspirin were found to be 2.210 
μg/ml and 6.696 μg/ml, for Clopidogrel were 2.614 
μg/ml and 7.922 μg/ml and for Rosuastatin were 0.219 
μg/ml and 0.664 μg/ml. The outcomes of robustness in 
the projected method exhibited no significant changes. 
The analytical outcomes of dropspecified that no 
interference due to common excipients was detected 
with the developed method.Degradation studies 
justified the method specificity for its planned 
application.Thus, the proposed method can be used for 
routine analysis of three drugs in their combined 
pharmaceutical dosage form. 
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Figure 1: Structure of Aspirin 
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Figure 2: Structure of Clopidogrel 
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Figure 3: Structure of Rosuvastatin 
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Figure 4: Overlay absorption spectrum for Aspirin, Clopidogrel and Rosuvastatin 
 
 
Figure 5: Standard Chromatograms of Aspirin, Clopidogrel and Rosuvastatin 
 
 
 
Figure 6: Calibration curve of Aspirin 
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Figure 7: Calibration Curve of Clopidogrel 
 
 
 
Figure 8: Calibration curve of Rosuvastatin 
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Figure 9: Chromatograms of (a) blank, (b)Aspirin, (c)Clopidogrel,(d) Rosuvastatin, (e) Standard 
Mixture and (f) Sample Mixture 
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Figure 10: Chromatograms of (a) Acid Degradation, (b) Base Degradation (c) Oxidative 
Degradation, (d) Thermal Degradation, (e) Photolytic Degradation 
 
Table 1: System suitability of proposed method 
 
Parameters Aspirin Clopidogrel Rosuvastatin 
Theoretical 
plates 
7285 4354 5303 
Resolution 4.190 -- 7.138 
Asymmetry 1.442 1.595 1.806 
Retention time 6.890 min 5.513 min 10.003 min 
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Table 2: Linearity results of Aspirin 
 
Linearity Level Concentration Area 
I 15 µg/ml 945.69 
II 22.5 µg/ml 1362.27 
III 30 µg/ml 1848.26 
IV 37.5 µg/ml 2278.29 
V 45 µg/ml 2834.92 
Correlation coefficient 0.9988 
Table 3: Linearity of Clopidogrel 
 
Linearity Level Concentration Area 
I 15 µg/ml 966.15 
II 22.5 µg/ml 1386.98 
III 30 µg/ml 1882.13 
IV 37.5 µg/ml 2420.67 
V 45 µg/ml 2992.04 
Correlation coefficient 0.9983 
 
Table 4: Linearity of Rosuvastatin 
 
Linearity Level Concentration Area 
I 2 µg/ml 675.55 
II 3 µg/ml 999.30 
III 4 µg/ml 1358.50 
IV 5 µg/ml 1688.31 
V 6 µg/ml 2089.22 
Correlation coefficient 0.9993 
Table 5: Results of Accuracy 
Sample Accuracy 
Standard 
Drug 
(µg/ml) 
Formulation 
(µg/ml) 
% of 
recovery 
S.D. 
% 
RSD 
ASP 
80% 12 15 99.409 1.226 1.23 
100% 15 15 98.548 0.201 0.20 
120% 18 15 98.733 0.329 0.33 
CLP 
80% 12 15 99.165 0.588 0.59 
100% 15 15 99.125 0.883 0.89 
120% 18 15 98.803 0.845 0.86 
ROS 
80% 1.6 2 100.546 1.261 1.25 
100% 2.0 2 100.636 0.579 0.58 
120% 2.4 2 100.945 0.554 0.55 
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Table 6: Results of Precision 
Injection Area of ASP Area of CLP Area of ROS 
Injection 1 1896.634 1974.274 1366.159 
Injection 2 1913.620 1947.761 1406.088 
Injection 3 1906.713 1946.649 1397.305 
Injection 4 1897.740 1931.744 1394.359 
Injection 5 1905.135 1939.288 1399.834 
Injection 6 1921.358 1955.738 1411.659 
Average 1906.867 1949.242 1395.901 
S.D. 9.4513 14.7172 15.8524 
% RSD 0.50 0.76 1.14 
Table 7: Result of Inter-day Precision 
Conc. (µg/ml) Area % RSD 
ASP CLP ROS ASP CLP ROS ASP CLP ROS 
15 15 2 984.591 1001.995 703.244 1.79 0.81 1.63 
30 30 4 1898.106 1936.329 1388.883 0.85 0.55 1.36 
45 45 6 2865.902 2926.618 2105.901 0.76 1.26 0.46 
Table 8: Result of Intra-day Precision 
Conc. (µg/ml) Area % RSD 
ASP CLP ROS ASP CLP ROS ASP CLP ROS 
15 15 2 945.647 969.978 686.509 1.05 1.67 1.77 
30 30 4 1901.478 1956.780 1388.422 0.21 1.78 1.37 
45 45 6 2860.596 2925.940 2094.360 0.41 1.39 0.60 
Table 9: Results of LOD and LOQ 
Parameter ASP (µg/ml) CLP (µg/ml) ROS (µg/ml) 
LOD 2.210 2.614 0.219 
LOQ 6.696 7.922 0.664 
Table 10: Results of Robustness 
Condition Variation 
Average Area % RSD 
ASP CLP ROS ASP CLP ROS 
Flow rate 
0.8 min 2119.549 2162.04 1549.696 0.40 0.61 1.66 
1.2 min 1597.141 1676.466 1167.175 1.57 0.81 0.74 
Mobile 
phase 
Buffer: 
Methanol 
62:38 
1783.385 1873.256 1294.865 1.48 1.30 0.40 
Buffer: 
Methanol 
58:42 
1909.592 2003.498 1398.270 0.72 1.04 1.25 
pH 
4.2 1947.387 2044.774 1415.070 0.90 1.15 1.06 
3.8 2000.735 2073.360 1464.667 1.46 0.64 1.25 
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Table 11: Stability study results 
 
Type of 
degradation 
Drug Peak Area 
of Standard 
Conditions Peak area 
Standard Sample 
Area of 
Std. 
% 
Deg. 
Area of 
Sample 
% 
Deg. 
Acid 
degradation  
ASP 1841.313 With 0.1N 
HCL; 4 hours at 
R.T. 
1349.474 26.71 1505.845 18.22 
CLP 1871.457 1302.935 30.38 1337.653 28.52 
ROS 1317.963 1105.702 16.11 1127.165 14.48 
Base 
degradation  
ASP 1841.313 With 0.1N 
NaOH; 4.5 
hours at R.T. 
1202.563 34.69 1127.425 38.77 
CLP 1871.457 1413.6 24.47 1459.401 22.02 
ROS 1317.963 919.86 30.21 941.735 28.55 
Oxidative 
degradation  
ASP 1841.313 With 3% H2O2; 
4 hours at R.T. 
1239.355 32.69 1248.991 32.17 
CLP 1871.457 1206.697 35.52 1268.518 32.22 
ROS 1317.963 1010.498 23.33 996.108 24.42 
Thermal 
degradation  
ASP 1841.313 For 4 hours at 
105
0
C 
1517.522 17.58 1475.024 19.89 
CLP 1871.457 1546.737 17.35 1555.102 16.90 
ROS 1317.963 862.096 34.59 838.415 36.39 
Photolytic 
degradation  
ASP 1841.313 For 3.5 hours in 
direct Sun light 
1441.711 21.70 1445.592 21.49 
CLP 1871.457 1465.913 21.67 1479.968 20.92 
ROS 1317.963 1057.021 19.80 1031.018 21.77 
 
Conclusion 
A simple, precise, accurate and rapid method was 
developed for simultaneous estimation of Aspirin, 
Clopidogrel and Rosuastatin from pure and its dosage 
forms. The preparation of mobile phase is easy and 
cost-effective. The recoveries of sample in the 
formulation were in good arrangement with their 
particular label claims.Henceforth, this method could 
be effortlessly and suitablyaccepted for routine 
analysisof Aspirin, Clopidogrel and Rosuastatin in pure 
form and its dosage form. 
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